Table 1

WASp mutations and expression in patients with WAS and patients with XLT

PatientExoncDNA nuclMutation*Predicted proteinProtein expressionPhenotype (clinical score)
W2 150 T>C L39P Decreased XLT (2) 
W3 150 T>C L39P Decreased XLT (2) 
W19 11 1476 T>A I481N Decreased XLT (1) 
W28 168 C>A T45K Decreased XLT (2) 
W29 257 G>A V75M Decreased XLT (2) 
W35 11 1378-1379 Del.GG G449 × 494 Decreased XLT (2) 
W27 10 1100-1003 Del C P356 × 445 Undetectable WAS (4) 
W39§ 692 Del A K231fs Undetectable WAS (4) 
W40§ 361-11_371 Del ggtatgtgcagGACTGCCAAGC D121fs Undetectable WAS (4) 
PatientExoncDNA nuclMutation*Predicted proteinProtein expressionPhenotype (clinical score)
W2 150 T>C L39P Decreased XLT (2) 
W3 150 T>C L39P Decreased XLT (2) 
W19 11 1476 T>A I481N Decreased XLT (1) 
W28 168 C>A T45K Decreased XLT (2) 
W29 257 G>A V75M Decreased XLT (2) 
W35 11 1378-1379 Del.GG G449 × 494 Decreased XLT (2) 
W27 10 1100-1003 Del C P356 × 445 Undetectable WAS (4) 
W39§ 692 Del A K231fs Undetectable WAS (4) 
W40§ 361-11_371 Del ggtatgtgcagGACTGCCAAGC D121fs Undetectable WAS (4) 

WASp indicates Wiskott-Aldrich syndrome protein; XLT, X-linked thrombocytopenia; nucl, nucleotide; and Del, deletion.

*

Mutations of WASP gene were identified in all patients by single-strand conformation polymorphism analysis or denaturing high-performance liquid chromatography and polymerase chain reaction sequencing.

Protein expression was evaluated by Western blotting and/or immunofluorescence and cytofluorimetric analysis.

Clinical score was determined according to Zhu et al.

§

Nomenclature of mutation as recommended by the Human Genome Variation Society (NM_000377.2).

Close Modal

or Create an Account

Close Modal
Close Modal